Clene (NASDAQ:CLNN) Major Shareholder Chidozie Ugwumba Sells 5,795 Shares

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 5,795 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $6.01, for a total transaction of $34,827.95. Following the transaction, the insider owned 271,774 shares of the company’s stock, valued at $1,633,361.74. This trade represents a 2.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Monday, May 4th, Chidozie Ugwumba sold 72,884 shares of Clene stock. The stock was sold at an average price of $6.80, for a total transaction of $495,611.20.
• On Thursday, April 30th, Chidozie Ugwumba sold 5,736 shares of Clene stock. The stock was sold at an average price of $6.08, for a total transaction of $34,874.88.
• On Wednesday, April 29th, Chidozie Ugwumba sold 12,170 shares of Clene stock. The stock was sold at an average price of $5.63, for a total transaction of $68,517.10.
• On Tuesday, April 28th, Chidozie Ugwumba sold 1,591 shares of Clene stock. The stock was sold at an average price of $5.90, for a total transaction of $9,386.90.
• On Tuesday, April 21st, Chidozie Ugwumba sold 61,345 shares of Clene stock. The stock was sold at an average price of $6.14, for a total transaction of $376,658.30.
• On Monday, April 20th, Chidozie Ugwumba sold 4,318 shares of Clene stock. The stock was sold at an average price of $6.12, for a total transaction of $26,426.16.
• On Friday, April 17th, Chidozie Ugwumba sold 25,040 shares of Clene stock. The stock was sold at an average price of $6.43, for a total transaction of $161,007.20.
• On Thursday, April 16th, Chidozie Ugwumba sold 7,748 shares of Clene stock. The stock was sold at an average price of $6.40, for a total transaction of $49,587.20.
• On Wednesday, April 15th, Chidozie Ugwumba sold 6,374 shares of Clene stock. The stock was sold at an average price of $6.48, for a total transaction of $41,303.52.
• On Thursday, April 2nd, Chidozie Ugwumba sold 24,925 shares of Clene stock. The stock was sold at an average price of $4.81, for a total transaction of $119,889.25.

Clene Price Performance

Clene stock opened at $6.58 on Wednesday. Clene Inc. has a 12-month low of $2.28 and a 12-month high of $13.50. The stock has a market capitalization of $77.51 million, a P/E ratio of -2.53 and a beta of 0.89. The firm’s 50-day moving average is $5.72 and its two-hundred day moving average is $6.45.

Clene (NASDAQ:CLNN) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.14). The firm had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.03 million. As a group, analysts forecast that Clene Inc. will post -1.99 EPS for the current year.

Hedge Funds Weigh In On Clene

A number of institutional investors have recently made changes to their positions in the business. SymBiosis Capital Partners LLC acquired a new position in shares of Clene in the 4th quarter valued at approximately $4,523,000. Scoggin Management LP raised its position in shares of Clene by 75.1% in the 3rd quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock valued at $1,506,000 after purchasing an additional 107,250 shares in the last quarter. Ensign Peak Advisors Inc raised its position in shares of Clene by 668.6% in the 4th quarter. Ensign Peak Advisors Inc now owns 114,361 shares of the company’s stock valued at $671,000 after purchasing an additional 99,481 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Clene by 8.0% in the 4th quarter. Geode Capital Management LLC now owns 82,079 shares of the company’s stock valued at $482,000 after purchasing an additional 6,090 shares in the last quarter. Finally, Lunt Capital Management Inc. raised its position in shares of Clene by 2.5% in the 3rd quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock valued at $315,000 after purchasing an additional 1,250 shares in the last quarter. 23.28% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

CLNN has been the subject of a number of analyst reports. D. Boral Capital restated a “buy” rating and issued a $23.00 price target on shares of Clene in a report on Monday. Weiss Ratings cut Clene from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, April 22nd. Canaccord Genuity Group restated a “buy” rating and issued a $48.00 price target on shares of Clene in a report on Friday, March 13th. Finally, HC Wainwright restated a “buy” rating and issued a $31.00 price target on shares of Clene in a report on Monday. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $33.25.

Clene News Roundup

Here are the key news stories impacting Clene this week:

• Positive Sentiment: FDA signaled the company may be able to pursue accelerated approval for CNM?Au8 based on neurofilament light (NfL) biomarker data — Clene expects to file an NDA in Q3 2026. This materially improves the regulatory pathway and the potential near?term value of CNM?Au8. FDA meeting / accelerated approval release
• Positive Sentiment: Sell?side support: HC Wainwright and D. Boral Capital recently reaffirmed/issued buy ratings with multi?fold price targets, underscoring bullish analyst expectations if clinical/regulatory progress continues. Analyst coverage (Benzinga)
• Neutral Sentiment: Investor outreach: Clene will present at May investor conferences (Emerging Growth Conference on May 6), which may provide additional updates but are not expected to change fundamentals immediately. Conference presentation announcement
• Negative Sentiment: Equity raise: Clene priced a registered direct offering of 1,000,000 shares at $7.00/share to raise ~ $7M to fund NDA preparation, trials, manufacturing and R&D. While proceeds reduce near?term cash risk, the offering increases share supply and signals reliance on external capital. Offering press release
• Negative Sentiment: Insider selling: Major shareholder Chidozie Ugwumba disclosed recent open?market sales (72,884 shares at $6.80 on May 4 and 5,795 shares at $6.01 on May 1), reducing their position substantially. Large insider sales can pressure price and raise questions about near?term sentiment from a top holder. SEC filing — insider transactions

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).